Ann Thornton
Analyst · Sidoti. Your line is open
Thank you, Russell. We grew organic sales 1.6% this quarter, while once again improving our gross profit margin and our overall profitability. This resulted in GAAP EPS of $0.9 per share, which was up 18.4% compared to the second quarter of last year. Non-GAAP EPS was just calculated as our GAAP EPS excluding the after-tax impact of amortization expense was $0.93 per share this quarter which was up 14.8% compared to the second quarter of last year. Our Americas and Asia region grew organic sales 1.2% and increased segment profit by 9.3% compared to last year's second quarter. And our Europe and Australia region grew organic sales 2.5% and increased segment profit by 11.9% compared to last year's second quarter. We executing extremely well in Europe despite a macro environment with minimal growth. We continue to integrate our businesses and identify opportunities to grow sales with existing customers as well as to convert new customers to our high-performance solutions. Our key financial takeaways this quarter are continued organic revenue growth despite slowing against macroeconomic trends. Non-GAAP EPS growth of 14.8%, significant improvement in gross profit margin, and a continued commitment to return funds to our shareholders. Now, I will turn to Slide number 4 for our quarterly sales trends. Organic sales grew 1.6% and foreign currency translation increased sales 0.8% this quarter while the impact of divestitures reduced sales by 3.5% resulting in a total sales decline of 1.1%. Slide number 5, outlines our quarterly gross profit and gross margin trending. Our gross profit margin improved by 220 basis points to 50.2% compared to 48% in the second quarter of last year. The significant improvement in our gross profit margin was the result of several factors, but with the primary being favorable product mix. Turning to Slide number 6, you'll find our SG&A expense trending. SG&A,was $91.3 million this quarter compared to $92.3 million in the second quarter of last year. As a percent of sales, SG&A,was consistent with last year at 28.3%. We're funding additional selling resources while reducing overall SG&A expenses through ongoing efficiency initiatives throughout our global businesses. Slide number 7, details our investments in research and development. This quarter, we once again increased our investment in R&D from $15.4 million to $16.8 million, which was 5.2% of sales. We're fully committed to our R&D efforts and we have several innovative new products planned for launch in the second half of this fiscal year. Moving to Slide number 8, you'll find our pre-tax earnings which increased 15.1% on a GAAP basis from $48.5 million to $55.8 million in the second quarter. Excluding amortization from both periods, pre-tax earnings increased 12.4% on a non-GAAP basis from $51.8 million to $58.2 million. Slide number 9, details earnings and EPS. Our trend of increasing earnings on a quarter-over-quarter basis continued this quarter. Our GAAP EPS increased by 18.4% and excluding the after-tax impact of amortization from both periods, our second quarter non-GAAP EPS increased 14.8% compared to last year. Turning to Slide number 10, you'll find a summary of our cash generation. Operating cash flow increased from $29.4 million in the second quarter last year to $36.1 million this quarter. Capital expenditures increased this quarter, because we purchased one of our facilities that had been previously leased, resulting in negative free cash flow due to this one-time purchase. We have been looking forward to closing this transaction because it secures a primary manufacturing location for us for the long term. On Slide number 11, you'll find the impact that our consistently strong cash generation has had on our balance sheet. We're currently in a net cash position of $95.8 million. So even as returning over $19 million to our shareholders in the form of dividends and share buybacks this quarter, the facility purchase and reducing our debt we are still in a net cash position. This gives us an incredible amount of flexibility in our capital allocation decisions. Our approach to capital allocation remains consistent, which is, to first use our cash to fully fund organic sales and efficiency opportunities. This includes investing in new product development, sales-generating resources, capability enhancing capital expenditures as well as automation focused CapEx. We will continue to deploy capital to productivity and sales growth opportunities throughout the economic cycle, that we focus on consistently increasing our dividend. This fiscal year, we announced our 38th consecutive annual increase in our dividends. After fully funding organic investments and our dividend, we then deploy our cash in a disciplined manner for either acquisitions where we have clear synergies or for opportunistic share buybacks when we see a disconnect between our intrinsic value in our trading price. Our incredibly strong balance sheet puts us in a position to execute additional growth opportunities through our R&D investments and sales resources, to acquire companies strategically, when the synergies are clear and the price is right and to return funds to our shareholders through dividends and share buybacks. On Slide number 12, you'll find our fiscal 2024 guidance. We are increasing the bottom end of our full year fiscal 2024 EPS guidance range of $3.70 to $3.95 on a GAAP basis and $3.85 to $4.10 on a non-GAAP basis to our new range of $3.80 to $3.95 on a GAAP basis, and $3.95 to $4.10 on a non-GAAP basis. Our outlook is based upon January 31st foreign currency exchange rates and it assumes continued economic expansion. Macroeconomic conditions do continue to slow in certain end markets and parts of Europe. So we now expect that organic sales growth will be in the low single-digits for the full fiscal year 2024. The other elements of our guidance remain consistent with an income tax rate of approximately 22%, depreciation and amortization of approximately $30 million to $32 million and capital expenditures of approximately $75 million, which is inclusive of approximately $55 million of CapEx for the purchase of the previously leased facility, which I mentioned, as well as the build-out of a new facility which will allow us to combine two lease leased locations into one owned location. Potential risks to our guidance among others include potential strengthening of the US dollar, inflationary pressures that we're unable to upsell to offset in a timely enough manner for an overall slowdown in economic activity. I'll now turn the call back over to Russell to cover our regional results and to provide some closing thoughts before Q&A. Russell?